Dr. John Cush RheumNow
6 years 5 months ago
Why are more MEN (severely?) affected in COVID-19? Men have higher levels of circulating ACE2 (unrelated to ACEi or ARB HTN meds) based on a Biobank study of 1485 men, 537 women. ACE2 is found in lungs, heart, kidneys, vessels & testes https://t.co/CWXevTNYWm
Dr. John Cush RheumNow
6 years 5 months ago
A new feature of COVID-19; "Covid toes" manifest as multifocal, asymmetric, erythema, ecchymoses, ischemic changes that blister or appear vasculitic. The toes, heel and soles can be affected. Healing in 12-20 days. https://t.co/Isqn9ebnQj
Dr. John Cush RheumNow
6 years 5 months ago
Subanalyses of Mobility and Monarch studies show that #RA patients with highest tertiles of IL-6 (and CRP) had more disease activity, more Xray damage and better responses (less Xray change) to Sarilumab (vs Adalimumab or MTX). https://t.co/5mTePETFAQ
Dr. John Cush RheumNow
6 years 5 months ago
1194 participants in Osteoarthritis Initiative shows 10 yr risk of incident Xray Knee OA was not increased by long term sitting, low-moderate physical activity (adjOR 0.69; 0.48-1.01) or strenuous phys activity (aOR 0.75; 0.53-1.07) https://t.co/7pCOwLpscr
The EXCEED study was a head-to-head trial of secukinumab (SEC) versus adalimumab (ADA) as first-line monotherapy in psoriatic arthritis (PsA) patients; this 52 week trial showed that while SEC failed to achieve clinical superiority over ADA, SEC treated patients demonstrated higher treatment retention rates and better PASI90 response rates.
Dr. John Cush RheumNow
6 years 5 months ago
"There's a rule in acting called "Don't play the result." If you have a character who's going to end up in a certain place, don't play that until you get there. Play each scene and each beat as it comes. And that's what you do in life: You don't play the result."
-Michael J. Fox
Dr. John Cush RheumNow
6 years 5 months ago
Why are more MEN (severely?) affected in COVID-19? Men have higher levels of circulating ACE2 (unrelated to ACEi or ARB HTN meds) based on a Biobank study of 1485 men, 537 women. ACE2 is found in lungs, heart, kidneys, vessels & testes https://t.co/CWXevTNYWm
Another lonely locked-down day. Seems like months. Rent is due, phone and EMR fees next week. Loan is pending. Seems impossible to treat complex diseases without touch and only computer screen rapport. And yet, it is a good day.
Dr. John Cush RheumNow
6 years 5 months ago
Anakinra studied in COVID(+) ARDS (nonICU) pts w/ high CRP L or ferritin; 29 high dose Anakinra vs 17 controls. At day 21, more survival with anakinra 90% vs. Controls 56% (p=0·009). Anakinra also more improved CRP+resp function (72 vs 50%) https://t.co/wxjlQG44Oc
Don't Drop Denosumab
Dr. Barry Gruber interviewed on spacing Denosumab treatments
Dr. John Cush RheumNow
6 years 5 months ago
The RheumNow Podcast is up - The Beat Goes On.... anakinra, nr-AxSpA, Smoking & GPA, PSS guidelines, IFNa, COVID and IL-6, HCQ,QTc, and Thromboses https://t.co/BsaALcHclv
Dr. John Cush RheumNow
6 years 5 months ago
European Medicines Agency (EMA), FDA and Health Canada have all issued warnings about the use of hydroxychloroquine & chloroquine in coronavirus, stating they should only be used in drug studies or hospitalized pts. https://t.co/HT39sT31Rq
Dr. John Cush RheumNow
6 years 5 months ago
American Hospital Association (AHA), in a new report, projected a loss of $202.6 billion from COVID-19 expenses and lost revenue for US hospitals and health systems from Mar 1 to Jun 30—about $50 billion in losses each month. https://t.co/pidOduwnDb
Dr. John Cush RheumNow
6 years 5 months ago
Anakinra works in CPPD. Metanalysis of biologics use finds 74 pts Rx with anakinra for refractory dz (85%) or w/ contraindications (23%). Anakinra resp seen in 81% of acute and 43% of chronic CPPD pts. Few adverse events reported (4.1%) https://t.co/PwJO4ta6i7
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
